Traders sold shares of Boston Scientific Corp. (NYSE:BSX) on strength during trading on Friday. $12.79 million flowed into the stock on the tick-up and $38.08 million flowed out of the stock on the tick-down, for a money net flow of $25.29 million out of the stock. Of all equities tracked, Boston Scientific Corp. had the 0th highest net out-flow for the day. Boston Scientific Corp. traded up $0.20 for the day and closed at $23.97

Several equities research analysts have recently commented on the company. JPMorgan Chase & Co. reissued a “buy” rating on shares of Boston Scientific Corp. in a report on Sunday, July 17th. TheStreet downgraded Boston Scientific Corp. from a “buy” rating to a “hold” rating in a report on Thursday, July 28th. Zacks Investment Research raised Boston Scientific Corp. from a “hold” rating to a “buy” rating and set a $26.00 price objective for the company in a report on Wednesday, July 13th. Piper Jaffray Cos. reissued an “overweight” rating and issued a $26.00 price objective on shares of Boston Scientific Corp. in a report on Wednesday, May 25th. Finally, Citigroup Inc. increased their price objective on Boston Scientific Corp. from $26.00 to $28.00 and gave the company a “buy” rating in a report on Wednesday, August 3rd. Six investment analysts have rated the stock with a hold rating and twenty-two have given a buy rating to the company’s stock. Boston Scientific Corp. has an average rating of “Buy” and an average price target of $24.70.

The company’s 50 day moving average price is $23.93 and its 200 day moving average price is $21.24. The stock’s market cap is $32.62 billion.

Boston Scientific Corp. (NYSE:BSX) last issued its quarterly earnings results on Thursday, July 28th. The company reported $0.27 EPS for the quarter, meeting analysts’ consensus estimates of $0.27. The firm had revenue of $2.13 billion for the quarter, compared to analysts’ expectations of $2.05 billion. During the same period in the prior year, the company earned $0.22 EPS. The firm’s quarterly revenue was up 15.4% on a year-over-year basis. On average, equities research analysts anticipate that Boston Scientific Corp. will post $1.10 EPS for the current fiscal year.

In related news, SVP John Bradley Sorenson sold 2,500 shares of the stock in a transaction dated Thursday, August 11th. The stock was sold at an average price of $23.90, for a total transaction of $59,750.00. Following the sale, the senior vice president now owns 12,615 shares of the company’s stock, valued at approximately $301,498.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP David A. Pierce sold 2,480 shares of the stock in a transaction dated Wednesday, July 20th. The stock was sold at an average price of $24.03, for a total value of $59,594.40. Following the sale, the senior vice president now directly owns 28,080 shares in the company, valued at approximately $674,762.40. The disclosure for this sale can be found here.

A number of hedge funds recently modified their holdings of the company. Ameriprise Financial Inc. boosted its stake in shares of Boston Scientific Corp. by 9.2% in the fourth quarter. Ameriprise Financial Inc. now owns 4,329,316 shares of the company’s stock worth $79,834,000 after buying an additional 364,201 shares during the period. Calvert Investment Management Inc. boosted its stake in shares of Boston Scientific Corp. by 32.0% in the fourth quarter. Calvert Investment Management Inc. now owns 63,661 shares of the company’s stock worth $1,174,000 after buying an additional 15,415 shares during the period. State of Tennessee Treasury Department boosted its stake in shares of Boston Scientific Corp. by 165.7% in the fourth quarter. State of Tennessee Treasury Department now owns 543,062 shares of the company’s stock worth $10,014,000 after buying an additional 338,662 shares during the period. Finally, Bank of Montreal Can boosted its stake in shares of Boston Scientific Corp. by 18.1% in the fourth quarter. Bank of Montreal Can now owns 522,744 shares of the company’s stock worth $9,639,000 after buying an additional 80,052 shares during the period.

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven core businesses: Interventional Cardiology, Peripheral Interventions (PI), Cardiac Rhythm Management (CRM), Electrophysiology (EP), Endoscopy, Urology and Pelvic Health, and Neuromodulation.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.